Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bullish stance on Iovance Biotherapeutics IOVA.

And retail traders should know.

We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IOVA, it often means somebody knows something is about to happen.

Today, Benzinga's options scanner spotted 9 options trades for Iovance Biotherapeutics.

This isn't normal.

The overall sentiment of these big-money traders is split between 55% bullish and 44%, bearish.

Out of all of the options we uncovered, there was 1 put, for a total amount of $76,650, and 8, calls, for a total amount of $946,290.

What's The Price Target?

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.0 and $20.0 for Iovance Biotherapeutics, spanning the last three months.

Insights into Volume & Open Interest

In terms of liquidity and interest, the mean open interest for Iovance Biotherapeutics options trades today is 4293.0 with a total volume of 2,481.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Iovance Biotherapeutics's big money trades within a strike price range of $5.0 to $20.0 over the last 30 days.

Iovance Biotherapeutics Call and Put Volume: 30-Day Overview

Noteworthy Options Activity:

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Current Position of Iovance Biotherapeutics

• With a trading volume of 3,292,420, the price of IOVA is down by -0.13%, reaching $15.0.
• Current RSI values indicate that the stock is may be approaching oversold.
• Next earnings report is scheduled for 43 days from now.

What The Experts Say On Iovance Biotherapeutics

A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $25.2.

• An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $32.
• An analyst from Barclays has decided to maintain their Overweight rating on Iovance Biotherapeutics, which currently sits at a price target of $22.
• An analyst from HC Wainwright & Co. has revised its rating downward to Buy, adjusting the price target to $32.
• Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Iovance Biotherapeutics with a target price of $21.
• An analyst from Piper Sandler has decided to maintain their Overweight rating on Iovance Biotherapeutics, which currently sits at a price target of $19.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Iovance Biotherapeutics, Benzinga Pro gives you real-time options trades alerts.